Business of Pain 2025 Annual Conference Abstract Submission Form Logo
  • Business of Pain 2025 Annual Conference

    Submission Deadline: October 1st, 2025
  • The Planning Committee for The Next Big Thing 2025 Conference Presented by Business of Pain, invites you to submit abstracts to be presented at the upcoming conference at the Eden Roc Hotel in Miami Beach, Florida. We are looking for cutting-edge science abstracts that present new products, procedures and data for outcome measures. We welcome medical students, residents and fellows to submit abstracts as well.

    General Information:
    The Business of Pain has reserved time for scientific poster sessions. ePosters will be available for viewing throughout the entirety of the conference. You are welcome and encouraged to bring handouts.

    Abstracts previously presented or published may not be submitted without modifications, original work must be changed or expanded, resulting in a new abstract.

    The Planning Committee will retain the copyright of the published abstracts. Awards will be presented to the top poster presenters.

    Submission Information:
    Please use the recommended abstract format:

    Introduction/Statement of the Problem, Materials and Methods, Results, and Conclusions. The text of your abstract may be up to 300 words.

    • In 300 words or less, provide an accurate, succinct, and informative representation of the content that will be presented in the paper.
    • Do not use abbreviations. Type in sentence case. Do not type in all caps.
    • Do not use the ampersand character (&) unless it is part of the company name.
    • Proofread for typographical, grammar, and syntax errors.

    All abstracts should be submitted electronically as Word documents (with a .doc extension)

    Questions about BoP 2025 Abstracts contact - Rosa McKenzie; rosa.scorah@gmail.com

    Policy on Commercial Support:
    Abstracts must avoid commercialism. Abstracts that constitute promotion and advertising will not be accepted. Statements should not be viewed as or considered representative of any formal stance or position taken on any subject, issue, or product by the BoP 2025 Planning Committee.

    Selection Criteria:
    Submissions will be reviewed and rated by members of the Scientific Planning Committee who have expertise in the clinical area to which the submission belongs. Each submission will be reviewed for its scientific or clinical importance, ethical practice, and study design.

    Abstract Poster winners will be recognized at the podium during the conference. The top 3 chosen will win a cash prize.

    Meeting Registration Guideline for Poster Winners:
    Poster winners can register for the meeting and pay the applicable registration fee, as the Business of Pain 2025 Conference will not waive the registration fee. Poster winners are also responsible for all personal expenses (e.g., travel, hotel). You are encouraged to register for the meeting and to reserve hotel accommodations as early as possible to ensure that space is available.


    For Registration and Hotel Information, please contact the planning committee at: Trista.mantra@gmail.com

    • Primary Presenter 
    • Co-Presenter 
    • Co-Presenter 2 
    • Co-Presenter 3 
    • Collapse Stopper 
    • Browse Files
      Drag and drop files here
      Choose a file
      Cancelof
    • Disclosures

    • Clear
    •  - -
    • By submitting this abstract, the presenting author certifies the following:

      The identical abstract has not been submitted to any other meeting. The material has not been accepted for publication before this submission. All the listed presenters have reviewed this abstract and agree to its submission. Upon acceptance, the presenting author accepts the commitment to possibly present the abstract at the 2024 Annual Conference.
    • Presenter Biographical Form

      This information must be submitted for the Primary Presenter only. Please type the information with your name and credentials exactly as you want them to appear in the published materials.
    • Disclosure of Financial Relationships

      All authors submitting abstracts for publications are required to disclose any relationships with industry that may direct bearing on relevant subject matter. The primary presenter must disclose any author/presenter who has relevant financial interest or other relationships occurring with the past 12 months with commercial companies or organizations.
    •  
    • Additional Form if needed 
    •  
    • Additional Form if needed 
    •  
    • Additional Form if needed 
    •  
    • Collapse Stopper 
    • FDA Disclosure

      If a device or drug requiring FDA approval is identified as an important component of your presentation, please list the device/drug and indicate the FDA status as either: Approved, Investigational Device/Drug, Not approved for distribution in the United States.
    • Device/Drug Status

    • Device/Drug Status

    • Device/Drug Status

    • Device/Drug Status

    • Device/Drug Status

    • Device/Drug Status

    • Should be Empty: